Equities research analysts expect Syndax Pharmaceuticals Inc (NASDAQ:SNDX) to post sales of $390,000.00 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Syndax Pharmaceuticals’ earnings. The lowest sales estimate is $380,000.00 and the highest is $400,000.00. Syndax Pharmaceuticals reported sales of $380,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 2.6%. The business is scheduled to report its next earnings report on Monday, November 4th.
On average, analysts expect that Syndax Pharmaceuticals will report full-year sales of $1.51 million for the current year, with estimates ranging from $1.50 million to $1.52 million. For the next financial year, analysts forecast that the company will post sales of $4.24 million, with estimates ranging from $1.50 million to $12.40 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Syndax Pharmaceuticals.
Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.03). The business had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.39 million. Syndax Pharmaceuticals had a negative return on equity of 108.44% and a negative net margin of 4,310.68%.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in shares of Syndax Pharmaceuticals by 52.5% in the second quarter. JPMorgan Chase & Co. now owns 5,522 shares of the company’s stock valued at $50,000 after buying an additional 1,902 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Syndax Pharmaceuticals by 1.6% during the 4th quarter. Northern Trust Corp now owns 175,492 shares of the company’s stock valued at $781,000 after acquiring an additional 2,690 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $36,000. Bank of New York Mellon Corp grew its holdings in shares of Syndax Pharmaceuticals by 7.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 70,899 shares of the company’s stock valued at $659,000 after acquiring an additional 4,837 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its holdings in shares of Syndax Pharmaceuticals by 39.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 18,314 shares of the company’s stock valued at $171,000 after acquiring an additional 5,162 shares in the last quarter. 62.76% of the stock is currently owned by institutional investors.
NASDAQ:SNDX traded up $0.83 during midday trading on Thursday, hitting $10.76. 356,643 shares of the stock were exchanged, compared to its average volume of 163,740. Syndax Pharmaceuticals has a one year low of $3.39 and a one year high of $11.11. The company has a market cap of $291.55 million, a P/E ratio of -3.68 and a beta of 2.41. The company’s 50-day moving average price is $9.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.90 and a quick ratio of 4.90.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
Featured Article: Institutional Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.